Literature DB >> 24577936

Treatment complications and survival in advanced laryngeal cancer: a population-based analysis.

Caitriona B O'Neill1, James P O'Neill, Coral L Atoria, Shrujal S Baxi, Martin C Henman, Ian Ganly, Elena B Elkin.   

Abstract

OBJECTIVES/HYPOTHESIS: Primary curative treatment of advanced laryngeal cancer may include surgery or chemoradiation, although recommendations vary and both are associated with complications. We evaluated predictors and trends in the use of these modalities and compared rates of complications and overall survival in a population-based cohort of older adults. STUDY
DESIGN: Retrospective population-based cohort study.
METHODS: Using Surveillance Epidemiology and End Results (SEER) cancer registry data linked with Medicare claims, we identified patients over 65 with advanced laryngeal cancer diagnosed 1999 to 2007 who had total laryngectomy (TL) or chemoradiation (CTRT) within 6 months following diagnosis. We identified complications and estimated the impact of treatment on overall survival, using propensity score methods.
RESULTS: The proportion of patients receiving TL declined from 74% in 1999 to 26% in 2007 (P < 0.0001). Almost 20% of the CTRT patients had a tracheostomy following treatment, and 57% had a feeding tube. TL was associated with an 18% lower risk of death, adjusting for patient and disease characteristics. The benefit of TL was greatest in patients with the highest propensity to receive surgery.
CONCLUSION: TL remains an important treatment option in well selected older patients. However, treatment selection is complex; and factors such as functional status, patient preference, surgeon expertise, and post-treatment support services should play a role in treatment decisions. LEVEL OF EVIDENCE: 2b. Laryngoscope, 124:2707-2713, 2014.
© 2014 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Treatment; complications; laryngeal cancer; survival

Mesh:

Year:  2014        PMID: 24577936      PMCID: PMC4821412          DOI: 10.1002/lary.24658

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  42 in total

1.  Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.

Authors:  Stephanie A Michal; David J Adelstein; Lisa A Rybicki; Cristina P Rodriguez; Jerrold P Saxton; Benjamin G Wood; Joseph Scharpf; Denise I Ives
Journal:  Head Neck       Date:  2011-10-22       Impact factor: 3.147

2.  Postoperative complications of salvage total laryngectomy.

Authors:  Ian Ganly; Snehal Patel; Jeanette Matsuo; Bhuvanesh Singh; Dennis Kraus; Jay Boyle; Richard Wong; Nancy Lee; David G Pfister; Ashok Shaha; Jatin Shah
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

3.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

4.  Cost comparison of surgery vs organ preservation for laryngeal cancer.

Authors:  Greg E Davis; Seth R Schwartz; David L Veenstra; Bevan Yueh
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2005-01

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer.

Authors:  Daniel J Givens; Lucy Hynds Karnell; Anjali K Gupta; Gerald H Clamon; Nitin A Pagedar; Kristi E Chang; Douglas J Van Daele; Gerry F Funk
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-12

7.  Laryngeal cancer treatment and survival differences across regional cancer centres in Ontario, Canada.

Authors:  P A Groome; B O'Sullivan; W J Mackillop; J Irish; K Schulze; L D Jackson; R J Bissett; P F Dixon; L J Eapen; S P Gulavita; J A Hammond; D I Hodson; R G Mackenzie; K M Schneider; P R Warde
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-09-09       Impact factor: 4.126

8.  Factors predictive of poor functional outcome after chemoradiation for advanced laryngeal cancer.

Authors:  Jonathan Staton; K Thomas Robbins; Lisa Newman; Sandeep Samant; Merry Sebelik; Francisco Vieira
Journal:  Otolaryngol Head Neck Surg       Date:  2002-07       Impact factor: 3.497

Review 9.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

Authors:  Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

10.  Factors predictive of survival in advanced laryngeal cancer.

Authors:  Amy Y Chen; Michael Halpern
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-12
View more
  11 in total

1.  Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Authors:  Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-04-01       Impact factor: 6.223

Review 2.  Organ Preservation Protocols in T4 Laryngeal Cancer: a Review of the Literature.

Authors:  Narayana Subramaniam; Deepak Balasubramanian; Rithvik Reddy; Krishnakumar Thankappan; Subramania Iyer
Journal:  Indian J Surg Oncol       Date:  2018-12-01

Review 3.  Conservative treatment for advanced T3-T4 laryngeal cancer: meta-analysis of key oncological outcomes.

Authors:  Giuditta Mannelli; Maria Silvia Lazio; Paolo Luparello; Oreste Gallo
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-08       Impact factor: 2.503

4.  Association of Modified Frailty Index Score With Perioperative Risk for Patients Undergoing Total Laryngectomy.

Authors:  Brandon Wachal; Matthew Johnson; Alissa Burchell; Harlan Sayles; Katherine Rieke; Robert Lindau; William Lydiatt; Aru Panwar
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-08-01       Impact factor: 6.223

5.  Open partial horizontal laryngectomy for T2-T3-T4a laryngeal cancer: oncological outcomes and prognostic factors of two Italian hospitals.

Authors:  Marco de Vincentiis; Antonio Greco; Flaminia Campo; Francesca Candelori; Massimo Ralli; Mario Di Traglia; Andrea Colizza; Francesca Cambria; Jacopo Zocchi; Valentina Manciocco; Giuseppe Spriano; Raul Pellini
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-03       Impact factor: 2.503

6.  Predictive and prognostic factors for patients with locoregionally advanced laryngeal carcinoma treated with surgical multimodality protocol.

Authors:  Gorkem Eskiizmir; Gokce Tanyeri Toker; Onur Celik; Kivanc Gunhan; Ayca Tan; Hulya Ellidokuz
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-10       Impact factor: 2.503

7.  Surgical vs Nonsurgical Treatment Modalities for T3 Glottic Squamous Cell Carcinoma.

Authors:  Maha Al-Gilani; S Andrew Skillington; Dorina Kallogjeri; Bruce Haughey; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-10-01       Impact factor: 6.223

8.  Long-term functional outcome after laryngeal cancer treatment.

Authors:  Lukas Anschuetz; Mohamed Shelan; Marco Dematté; Adrian D Schubert; Roland Giger; Olgun Elicin
Journal:  Radiat Oncol       Date:  2019-06-11       Impact factor: 3.481

9.  Alternative Payment Models in Medical Oncology: Assessing Quality-of-Care Outcomes Under Partial Capitation.

Authors:  Derek Ems; Sharanya Murty; Bryan Loy; Judith Gallagher; Laura E Happe; Teresa L Rogstad; Debra Finnel; Jimmy D Fernandez
Journal:  Am Health Drug Benefits       Date:  2018-10

10.  Comparison of Treatment Outcomes for T3 Glottic Squamous Cell Carcinoma: A Meta-Analysis.

Authors:  Bo Hae Kim; Sung Joon Park; Woo-Jin Jeong; Soon-Hyun Ahn
Journal:  Clin Exp Otorhinolaryngol       Date:  2018-02-22       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.